 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12340/13424 (92%)
Visitors : 1973820
Online Users : 165
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/16715
|
| Title: | Integrating ultrabright polymer dots and stereo NIR-II imager for assessing anti-angiogenic drugs in oral cancer model |
| Authors: | Huang, BH;Li, FY;Su, SP;Chen, CT;Chang, KW;Yang, MH;Chen, MC;Chiang, HK;Chan, YH;Lee, YJ |
| Contributors: | Institute of Biotechnology and Pharmaceutical Research |
| Abstract: | The development of efficient platforms for the evaluation of anti-angiogenic agents is critical in advancing cancer therapeutics. In this study, we exploited an ultrabright semiconducting polymer dots (Pdots) integrating with a three-dimensional (3D) near-infrared-II (NIR-II) fluorescence imaging system designed to assess the efficacy of potent anti-angiogenic agents PX-478 and BPR0C261 in an oral squamous cell carcinoma (OSCC) tumour model, which depends on angiogenesis for dissemination. PX-478, a hypoxia-inducible factor-1 alpha (HIF-1 alpha) inhibitor, and BPR0C261, a microtubule-disrupting agent, were administrated into tumour-bearing mice established using murine MTCQ1 tongue cancer cells through intraperitoneal injection and oral gavage, respectively. Our findings showed that PX-478 and BPR0C261 significantly inhibited tumour growth and extended the life span of tumour-bearing mice without decreasing the body weights. The Pdots-based NIR-II vascular imaging demonstrated that the tumour vascularity was suppressed by PX-478 and BPRC0261. Accordingly, the excised tumours treated with anti-angiogenic agents showed less blood vessels than that treated with vehicles. The expression of endothelial markers CD31 was also found to be reduced in tumours treated with PX-478 and BPRC0261 using immunohistochemical (IHC) staining and Western blot analysis. Furthermore, PX-478 could suppress the expression of HIF-1 alpha and vascular endothelial growth factor-A (VEGF-A), but BPRC0261 only suppressed VEGF-A. Taken together, this innovative 3D NIR-II imaging system combining the biocompatible Pdots with unique optical specificity enables non-invasive, real-time monitoring the efficacy of anti-angiogenic compounds. |
| Date: | 2025-01-05 |
| Relation: | Journal of Cellular and Molecular Medicine. 2025 Jan 05;29(1):Article number e70324. |
| Link to: | http://dx.doi.org/10.1111/jcmm.70324 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1582-1838&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:001389839500001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85214442629 |
| Appears in Collections: | [陳炯東] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI001389839500001.pdf | | 12751Kb | Adobe PDF | 6 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
